Copy Link Print Information

Cetuximab

(Synonyms: C225; IMC-C225)
55 Cited Publications
Avis client

Based on 55 publication(s) in Google Scholar

Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

  • Pureté: 99.81%
  • CAS No.: 205923-56-4
  • Masse moléculaire:145.54 kDa
  • Stockage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Experimental Validation Results for Cetuximab
  • Experimental Validation Results for Cetuximab
  • Experimental Validation Results for Cetuximab
  • Experimental Validation Results for Cetuximab
  • Experimental Validation Results for Cetuximab
  • Experimental Validation Results for Cetuximab
  • Experimental Validation Results for Cetuximab
  • Experimental Validation Results for Cetuximab
  • Experimental Validation Results for Cetuximab
  • Cetuximab Chemical Structure
    Cetuximab Chemical Structure
CAS No.: 205923-56-4
Size
Prix
Stock
Quantité
Amount: USD 0.00
Please select quantity
or
or

* Veuillez sélectionner la quantité avant d'ajouter des articles.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Cetuximab Product Recommendations:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Trouvez votre distributeur local Your local distributor: Hycultec GmbHHycultec
  • Activité biologique
  • Chemical Information
  • Pureté et documentation
  • Références
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Cetuximab

More
Customer Validation & Images
WBIHCCell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • WB
  • Cell Proliferation/Viability Assay
  • WB
  • IHC
  • Cell Proliferation/Viability Assay
  • WB

Voir tous les produits spécifiques à Isoform Radionuclide-Drug Conjugates (RDCs)

More

Voir tous les produits spécifiques à Isoform EGFR

More
Keywords
MOQ
Minimum order quantity
100 mg

Obtenir un devis En stock

Other size
Obtenir un devis
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Enregistrer
Sign in to MedChemExpress
Enregistrer un nouveau compte

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 1/16

    Human IgG1 kappa

  • 1/16

    Cetuximab has a significant ADCC effect on A431 cells in a dose-dependent manner.The EC50 for this effect is 43.50 and 39.11 ng/mL.

  • 1/16

    Cetuximab purchased from MedChemExpress. Usage Cited in: Theranostics. 2024 Aug 26;14(14):5443-5460. [Abstract]

    Customer Validation
     Cell viability by administrating various concentrations of cetuximab (Cmab) (20-160 μg/mL) and 25 μM HNK in HCT116 and LoVo cells.

  • 1/16

    Cetuximab purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Oct 22;134(24):e182217. [Abstract]

    Customer Validation
     Top: Western blots showing protein expression of MOGAT3 in RKO, RKO EC-R, HT29, and HT29 EC-R cells. Representative blots are shown. MOGAT3KO RKO EC-R and HT29 EC-R, along with RKO EC-R-CTRL and HT29 EC-R-CTRL cell lines, were exposed to 2 μM encorafenib/4 μM cetuximab for 96 hours. Bottom: Relative OD value was assessed to determine cell viability by the CCK-8 assay (n = 3).

  • 1/16

    Cetuximab purchased from MedChemExpress. Usage Cited in: J Control Release. 2024 Nov:375:643-653. [Abstract]

    Customer Validation
     Cell viability of RKO cells after treated by different concentrations of dabrafenib and cetuximab. The concentration gradient of dabrafenib and cetuximab varied from 0.39 to 50 μg/mL.

  • 1/16

    Cetuximab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Feb 1;13(1):594. [Abstract]

    Customer Validation
     Cetuximab (1.5 mg/kg; i.p.; single dose). Quantitative analysis of P-EGFR in tumor sections observed by western blot analysis

  • 1/16

    Cetuximab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Feb 1;13(1):594. [Abstract]

    Customer Validation
     Cetuximab (1.5 mg/kg; i.p.; single dose). Quantitative analysis of P-EGFR in tumor sections observed by IHC analysis.

  • 1/16

    Cetuximab purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Apr 6;10(11):5107-5119. [Abstract]

    Customer Validation
     The effect of cetuximab and β-elemene in combination (25 μg/mL) with other cell death inhibitors on the cell viability of KRAS mutant HCT116 and Lovo cells after the treatment for 24 h.

  • 1/16

    Cetuximab purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Apr 6;10(11):5107-5119. [Abstract]

    Customer Validation
     The expression of positive regulatory proteins for ferroptosis (HO-1 and transferrin) and the negative regulatory proteins for ferroptosis (GPX4, SLC7A11, FTH1, glutaminase, and SLC40A1) were detected by western blotting after the treatment (β-elemene 125 µg/mL, cetuximab 25 µg/mL) for 24 h.

  • Cetuximab Chemical Structure
    1/16
  • Cetuximab
  • Cetuximab has a significant ADCC effect on A431 cells in a dose-dependent manner.The EC50 for this effect is 43.50 and 39.11 ng/mL.